• By ICR Secretariat
  • Posted Thursday, October 13, 2022

OPTIMA announce AstraZeneca and Mutabor as official partners


The companies will aim to improve treatment for patients with prostate, breast and lung cancer

The Innovative Medicines Initiative (IMI) – a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) – has announced the launch of the public-private research programme OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence).